<DOC>
	<DOC>NCT00366431</DOC>
	<brief_summary>The primary purpose of the protocol is to evaluate the safety, efficacy, and tolerability of MOA-728 in subjects with Opioid-Induced Bowel Dysfunction (OIBD) with associated chronic non-malignant pain.</brief_summary>
	<brief_title>Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Analgesics, Opioid</mesh_term>
	<criteria>Adult outpatients with opioidinduced bowel dysfunction and chronic nonmalignant pain. Taking oral, transdermal, intravenous, or subcutaneous opioids. Willingness to discontinue all prestudy laxative therapy and utilize only study permitted rescue laxatives. History of chronic constipation before the initiation of opioid therapy. Other GI disorders known to affect bowel transit. Women who are pregnant, breastfeeding, or plan to become pregnant.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>OIBD</keyword>
	<keyword>OIC</keyword>
	<keyword>Opioid</keyword>
	<keyword>Constipation</keyword>
	<keyword>Laxative</keyword>
</DOC>